Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
This study has been completed.
First Received: June 14, 2002   Last Updated: May 3, 2007   History of Changes
Sponsor: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov Identifier: NCT00039910
  Purpose

Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts. This study will test the safety and efficacy of the investigational drug in the prevention of thrombocytopenia in patients with recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL), or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine, and Cisplatin) chemotherapy.


Condition Intervention Phase
Non-Hodgkin Lymphoma
Hodgkin Disease
Thrombocytopenia
 Drug: (PN-152,243)/ PN-196,444
 Phase III

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy

Resource links provided by NLM:

MedlinePlus related topics: Hodgkin  Disease Lymphoma
U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • To evaluate the effectiveness of primary prophylaxis with intravenous rhTPO versus placebo in reducing the cumulative proportion of patients who experience severe chemotherapy-induced thrombocytopenia.

Secondary Outcome Measures:
  • Identify the effect of rhTPO on the number of platelet transfusions
  • Evaluate the severity and duration of thrombocytopenia and neutropenia associated with rhTPO prophylaxis
  • Quantify the effect of rhTPO on the occurrence of any bleeding events associated with thrombocytopenia
  • Assess the likelihood that patients were to have adequate hematologic recovery to allow on-time chemotherapy administration in the subsequent cycles
  • Assess the safety of multiple IV doses of rhTPO
  • Determine the occurrence and clinical implications of any anti-TPO antibodies
  • Assess the antitumor activity of DHAP chemotherapy
  • Evaluate the impact of rhTPO prophylaxis on health economics/cost effectiveness
  • Evaluate the impact of rhTPO prophylaxis on patient quality of life

Estimated Enrollment: 240
Study Start Date: July 2000
Study Completion Date: March 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease and be scheduled for a minimum of 2 cycles of DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy

Exclusion Criteria:

  • Patients must not have active bleeding (exclusions do apply) or history of platelet disorder
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00039910

  Hide Study Locations
Locations
United States, Arizona
Pfizer Investigational Site
Phoenix, Arizona, United States, 85023
United States, California
Pfizer Investigational Site
Orange, California, United States, 92868
Pfizer Investigational Site
La Jolla, California, United States, 92037
Pfizer Investigational Site
Los Angeles, California, United States, 90033-0804
Pfizer Investigational Site
Los Angeles, California, United States, 90089
Pfizer Investigational Site
Los Angeles, California, United States, 90036
Pfizer Investigational Site
Los Angeles, California, United States, 90048
Pfizer Investigational Site
Loma Linda, California, United States, 92354
United States, Florida
Pfizer Investigational Site
Tamarac, Florida, United States, 33321
United States, Illinois
Pfizer Investigational Site
Chicago, Illinois, United States, 60637
Pfizer Investigational Site
Chicago, Illinois, United States, 60640
United States, Louisiana
Pfizer Investigational Site
Lake Charles, Louisiana, United States, 70601
United States, Michigan
Pfizer Investigational Site
St. Joseph, Michigan, United States, 49085
Pfizer Investigational Site
Detroit, Michigan, United States, 48202
Pfizer Investigational Site
Southfield, Michigan, United States, 48076
United States, Missouri
Pfizer Investigational Site
Jefferson City, Missouri, United States, 65109
Pfizer Investigational Site
Jefferson City, Missouri, United States, 90048
United States, Nebraska
Pfizer Investigational Site
Omaha, Nebraska, United States, 68198
United States, New York
Pfizer Investigational Site
Brooklyn, New York, United States, 11235
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27705
United States, Oregon
Pfizer Investigational Site
Coos Bay, Oregon, United States, 97420
United States, Pennsylvania
Pfizer Investigational Site
Hershey, Pennsylvania, United States, 17033
United States, Tennessee
Pfizer Investigational Site
Bristol, Tennessee, United States, 37620
United States, Virginia
Pfizer Investigational Site
Abingdon, Virginia, United States, 24210
Pfizer Investigational Site
Abingdon, Virginia, United States, 24211
Pfizer Investigational Site
Lebanon, Virginia, United States, 24266
Pfizer Investigational Site
Marion, Virginia, United States, 24354
Australia, Victoria
Pfizer Investigational Site
East Melbourne, Victoria, Australia, 3002
France
Pfizer Investigational Site
Tours, France, 37044
Pfizer Investigational Site
Paris, France
Greece, Macedonia
Pfizer Investigational Site
Thessaloniki, Macedonia, Greece, 540 07
Hong Kong, New Territories
Pfizer Investigational Site
Shatin, New Territories, Hong Kong
Poland
Pfizer Investigational Site
Warsaw, Poland
Pfizer Investigational Site
Lodz, Poland, 93-510
Russian Federation
Pfizer Investigational Site
Moscow, Russian Federation, 125167
Pfizer Investigational Site
Moscow, Russian Federation, 115478
Singapore
Pfizer Investigational Site
Singapore, Singapore, 169610
Pfizer Investigational Site
Singapore, Singapore, 169608
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers: 444-ONC-0003-0019
Study First Received: June 14, 2002
Last Updated: May 3, 2007
ClinicalTrials.gov Identifier: NCT00039910     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lymphatic Diseases
Neoplasms
Immunoproliferative Disorders
Neoplasms by Histologic Type
Thrombocytopenia
Immune System Diseases
 Hematologic Diseases
Blood Platelet Disorders
Lymphoproliferative Disorders
Lymphoma, Non-Hodgkin
Lymphoma
Hodgkin Disease

ClinicalTrials.gov processed this record on November 25, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services